Aprepitant is indicated for:
Population group: both men and women, only adults (18 years old or older)
Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adolescents (12 years - 18 years old)
Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adolescents from the age of 12.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Aprepitant is contraindicated in the following cases: